<u>DeTox</u>: An *in silico* Alternative to Animal Testing for Predicting <u>Developmental Tox</u>icity Potential

Ricardo Scheufen Tieghi

ricat@unc.edu

UNC Eshelman School of Pharmacy

Division of Chemical Biology and Medicinal Chemistry



Conflict of Interest Statement

Alexander Tropsha and Eugene Muratov are co-founders of *Predictive LLC*, which develops novel computer methodologies for the prediction of toxicity endpoints.

All other authors declare no conflicts of interest.



Developmental Toxicity Definition

- Toxicological endpoint for hazard and risk assessment of chemicals affecting fetal growth, structural formation, organ function, or survival before maturity.
- Traditionally evaluated with *in vivo* studies such as the OECD Prenatal Development
 - Toxicity Study (TG 414) and whole embryo culture assays in rats and rabbits.





Challenges of Animal Testing for Developmental Toxicity



• Expensive: \$128,000+



• Time-consuming



• Raises ethical concerns



• Human-relevance uncertainty

US EPA Cost Estimates of Studies for Pesticide Registration. 2018.

ESHELMAN SCHOOL

OF PHARMACY

Bailey, J., et al. (2005). Biogenic Amines.



Reported Predictive Power of *in vivo* **Developmental Toxicity**

Volume 149, Issue 20 October 2022

Development

SPOTLIGHT | 22 SEPTEMBER 2022

In vitro models of human development and their potential application in developmental toxicity testing $\widehat{\odot}$ Mirjam Niethammer, Tanja Burgdorf, Elisa Wistorf, Gilbert Schönfelder, Mandy Kleinsorge \blacksquare \bigcirc

+ Author and article information Development (2022) 149 (20): dev200933 https://doi.org/10.1242/dev.200933

Positive Predictability Challenges



60-70% concordance across 1400 substances

Inter-

species

Variability

WellBeing International WBI Studies Repository

2005

The Future of Teratology Research is In Vitro

Jarrod Bailey University of Newcastle-upon-Tyne

Andrew Knight

Jonathan Balcombe Physicians Committee for Responsible Medicine





Alternatives to Animal Testing



- NAMs: New Approach Methodologies
- NIH Complement-ARIE for NAMs
- QSAR: Quantitative-Structure Activity

Relationship



Data Ecosystem



14

Need for Improved Developmental Toxicity Testing

teratogens,





an *in* offers DeTox silico \bullet alternative to animal testing for developmental toxicity

RISK



¹Lund, Addiction (2012). ²Niethammer, Development (2022)

ESHELMAN SCHOOL OF PHARMACY

Machine Learning (ML) Overview:

• Analyze impact of many factors on an outcome





Slide inspired by Dr. Kristin Isaacs (EPA)

Methodology



Data Collection



Definition of Developmental Toxicants:

- Binary Classifications (developmentally toxic vs. non-toxic)
 - Toxic: Presence of any developmental abnormality
 - Non-toxic: No significant adverse outcomes
- Adverse Outcomes:
 - Malformations, structural abnormalities
 - Spontaneous abortions
 - Cognitive deficits
 - Altered growth
 - Functional/behavioral changes

Schardein, J. L. Teratogenesis, Carcinogenesis, and Mutagenesis 1987, 7 (3), 255–271.

Data Collection and Outcome Labeling





ESHELMAN SCHOOL

OF PHARMACY

Data Collection and Outcome Labeling

Reference compounds for alternative test methods to indicate developmental neurotoxicity (DNT) potential of chemicals: example lists and criteria for their selection and use

Michael Aschner¹, Sandra Ceccatelli², Mardas Daneshian³, Ellen Fritsche⁴, Nina Hasiwa³, Thomas Hartung^{3,5}, Helena T. Hogberg⁵, Marcel Leist^{3,6,7}, Abby Li⁸, William R. Mundy⁹, Stephanie Padilla⁹, Aldert H. Piersma^{10,11}, Anna Bal-Price¹², Andrea Seiler¹³, Remco H. Westerink¹⁴, Bastian Zimmer¹⁵, and Pamela J. Lein^{16,17}



Review article

Neurotoxicology and Teratology Volume 93, September–October 2022, 107117



An expert-driven literature review of "negative" chemicals for developmental neurotoxicity (DNT) *in vitro* assay evaluation

Melissa M. Martin^a, <u>Nancy C. Baker^d</u>, <u>William K. Boyes^{c1}</u>, <u>Kelly E. Carstens^a</u>, <u>Megan E. Culbreth^a</u>, <u>Mary E. Gilbert^c</u>, <u>Joshua A. Harrill^a</u>, <u>Johanna Nyffeler^{a e}</u>, <u>Stephanie Padilla^a</u>, Katie Paul Friedman^b, Timothy J. Shafer^a 은 전



ESHELMAN SCHOOL

OF PHARMACY

Additional 450 Records!

Data Collection courtesy of Marielle Rath

Results of Data Curation

INITIAL LIST OF SMILES					
Removal of inorganics		FDA - DailyMed	TERIS	Mundy 2009	Aschner
and mixtures	Initial number of records	46943	293	108	75
Structural conversion, cleaning of salts	Removal of inconsistent data	42075	290	105	73
2 Normalization of specific chemotypes	Removal of mixtures, inorganics, and cleaning/removal of salts	21316	275	89	62
tautomeric forms	Normalization of specific chemotypes	21023	275	87	62
Removal of duplicates	Removal of Unclassified Compounds	4023	-	86	-
4 Manual inspection CURATED DATASET	Final number of unique compounds after removing duplicates	221	275	86	61

Fourches D, et al. J Chem Inf Model. 2010 50(7):1189-204.

ESHELMAN SCHOOL

OF PHARMACY

Preliminary Dara Curation Courtesy of Marielle Rath

Verification of Non-Toxic Compounds and Trimester-Specific Literature Search

- Literature search
 - "Compound" AND "Trimester" AND "teratogen" or "developmental toxicity"



- Only included studies done under OECD or EPA guidelines
 - Testing done in rabbits, rats, or mice OR
 - Human studies with 50+ individuals

• Updated compound outcome if newer studies showed **any** of the adverse effects linked to developmental toxicity



Datasets Summary





384 Compounds Collected After Curation and Activity Verification





Dataset



Chemical Space Analysis: Class-Specific Grouping



ESHELMAN SCHOOL

OF PHARMACY

- Supervised Classification
- Morgan descriptors 2048 bits and radius 2
- Filtered low var. descriptors.
- Dimensionality reduction using SVM.



Moreira-Filho, J. et al *J Cheminform* **2024**, *16* (1), 101.

Chemical Space Analysis Reveals Few Activity Cliffs

ESHELMAN SCHOOL

OF PHARMACY



Moreira-Filho, J. et al J Cheminform 2024, 16 (1), 101.



24 Binary Classification Models Developed

- 24 Binary Classification Models
- Descriptors:
 - Topological Fingerprints (ECFP4)
 - Structural Fingerprints (MACCS)
- ML Algorithms:
 - Random Forest (RF)
 - Light Gradient-Boosting Machine (LightGBM)
- Support Vector Machine (SVM)

ESHELMAN SCHOOL

OF PHARMACY



- First Trimester
- Second Trimester
- Third Trimester
- Overall

Trimester-Specific Model Performance





Model Deployment



ESHELMAN SCHOOL

OF PHARMACY

<image>



DeTox Web tool Sketch Compound OR Input SMILES List Get Report with Fragment Contribution Maps

21



This is an online web portal to predict developmental toxicity, described in "PregPred: an In-Silico Alternative to Animal Testing for Predicting Developmental Toxicity Potential". To use, enter SMILES in the box below, or draw a compound and hit load SMILES, then click "Get Properties". Results will appear below. By default all models for all endpoints will be run. You can choose to turn off certain endpoints in the options sidebar. Fragment contribution maps are generated with RDKit. To turn on the maps, check the 'Display contribution maps' in the options sidebar. It defaults to off because the maps will increase the runtime significantly, so if using please be patient. More information about these maps can be found here.

For the applicability domain calculation (AD), an ensemble confidence approach is used such that if the average prediction confidence of the ensemble of models is above 0.6, the prediction is considered "inside" the AD

Please cite 'PregPred: an In-Silico Alternative to Animal Testing for Predicting Developmental Toxicity Potential'. Models and code for this webserver can be found here.



Results

OCCc1c(C)[n+](cs1)Cc2cnc(C)nc2N



Overall Toxicity Non-toxic Confidence: 0.7142227618148298 Applicability Domain: Inside







Model Performance Comparison to CAESAR



UNC ESHELMAN SCHOOL OF PHARMACY

Model External Validation Performance

Cassano et al. Chemistry Central Journal 2010, 4(Suppl 1):S4 http://www.journal.chemistrycentral.com/content/4/S1/S4

PROCEEDINGS

Open Access

Journal

Chemistry Central

CAESAR models for developmental toxicity

Antonio Cassano¹, Alberto Manganaro¹, Todd Martin², Douglas Young², Nadège Piclin³, Marco Pintore³, Davide Bigoni⁴, Emilio Benfenati^{1*}

From CAESAR Workshop on QSAR Models for REACH

- 292 chemicals with FDA labels for developmental toxicity
- Compounds outside model's training set were predicted using web platform
 - ~200 compounds per dataset



³Cassano, Chemistry Central (2009).



Virtual Screening of DNT-DIVER



DNT-DIVER

- 87 neurodevelopmental toxicants
- Compounds not included in training set were predicted
- 15 shown are inside Applicability Domain for all 4 models
- Consensus predictions by the web platform

ESHELMAN SCHOOL

OF PHARMACY



Conclusions:

In silico approaches

Fast and costeffective alternative to animal testing.





Future Directions: NAMs for Developmental Neurotoxicity Mechanistic Analysis

- Initial Guidance published in Nov. 2023.
- Integrates a battery of 17 *in vitro* assays covering key DNT processes



OECD > Publications > Initial Recommendations on Evaluation of Data from the Developmental Neurotoxicity (DNT) In-Vitro Testing Battery

Initial Recommendations on Evaluation of Data from the Developmental Neurotoxicity (DNT) In-Vitro Testing Battery

Report

More info 🚯

OECD Series on Testing and Assessment • 3 November 2023





Constructing a Developmental Neurotoxicity Knowledge Graph (DNT-KG)



Slide adapted from Jon-Michael Beasley, PhD

OF PHARMACY

Knowledge Graphs Can Integrate Toxicology Datasets for Mechanistic Insights



ROBOKOP KG (https://robokop.renci.org/)

ESHELMAN SCHOOL

OF PHARMACY

Acknowledgements

<u>Graduate Students:</u> Marielle Rath James Wellnitz Enes Kelestemur Holli-Joi Sullivan, PhD Jon-Michael Beasley, PhD

<u>Post-Doctoral</u> Cleber Melo-Filho, PhD, PhD José Teófilo Moreira-Filho, PhD

Principal Investigators Alexander Tropsha, PhD Eugene Muratov, PhD Helena T. Hogberg-Durdock, PhD Nicole Kleinstreuer, PhD









NICEATM Group

in silico



Molecular Modeling Lab

https://detox.mml.unc.edu/

Complement-ARIE

Data Ecosystem

in chemico

UNC ESHELMAN SCHOOL OF PHARMACY

ricat@ad.unc.edu

Advancing Medicine for Life 30

in vitro